North Carolina is currently home to 2622 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Reliability of Pupil Response to Acute Pain
NCT02628314
Recruiting
The purpose of this research study is to test whether researchers can reliably measure the response pupils have when an acute painful stimulus is experienced. Changes in the size of the pupil of the eye can be an indicator of brain activity in a region of the brain that is important for feeling pain.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/27/2024
Locations: Wake Forest Baptist Medical Center, Winston-Salem, North Carolina
Conditions: Pain, Osteoarthritis
Register for Updates
Precision Nudging for Hypertension Management: Observational Study
NCT06354192
Recruiting
The purpose of the proposed observational study is to explore the relations between data-driven personalization and equitable health outcomes in a digital health intervention (DHI) for hypertension management. In the current intervention, behavioral reinforcement learning is applied to personalize intervention content to maximize the behavioral outcomes of three target behaviors critical for effective hypertension management: clinical encounters, medication adherence, and self-monitoring of bloo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Cone Health clinics, Greensboro, North Carolina
Conditions: Hypertension
Register for Updates
RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)
NCT06305806
Recruiting
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic ta... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: All sites listed under NCT06305780, Durham, North Carolina
Conditions: Long COVID, Long Covid19, Long Covid-19
Register for Updates
RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)
NCT06305793
Recruiting
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic ta... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: All sites listed under NCT06305780, Durham, North Carolina
Conditions: Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19
Register for Updates
Comparing Cognitive-Behavioral Therapy Versus Mindfulness-Based Therapy for Autistic Adults
NCT06060860
Recruiting
Autistic adults are at a greater risk for mental health problems compared to the general population, with 50% meeting criteria for a co-occurring psychiatric condition. Depression and anxiety are the most common of these conditions among autistic adults, contributing to long-term detrimental effects on health, day-to-day functioning, and quality of life. This study will conduct the first large-scale head-to-head comparison of the two most widely studied mental health interventions for autistic a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Autism Spectrum Disorder, Depression, Anxiety
Register for Updates
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
NCT05795595
Recruiting
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2024
Locations: Research Site 4, Durham, North Carolina
Conditions: Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma, Malignant Pleural Mesothelioma
Register for Updates
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
NCT05230537
Recruiting
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/24/2024
Locations: Duke Eye Center Research, Durham, North Carolina
Conditions: Age-Related Macular Degeneration
Register for Updates
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
NCT04770870
Recruiting
The H3 TAR Prosthesis was approved by FDA (P160036) on June 4, 2019. Continued approval of the premarket approval application (PMA) is contingent upon the submission of periodic reports (Annual Report), required under 21 CFR 814.84. In order to provide continued reasonable assurance of the safety and effectiveness of the PMA device, data from this post-approval study must be submitted to FDA in a PMA Post-Approval Study Report per the requirements set forth in the approval.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/24/2024
Locations: Duke Orhtopaedics Arringdon, Morrisville, North Carolina
Conditions: Osteoarthritis Ankle, Post-Traumatic Osteoarthritis of Ankle, Osteoarthritis of Ankle Secondary to Inflammatory Arthritis (Disorder)
Register for Updates
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
NCT03118986
Recruiting
Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact w... Read More
Gender:
ALL
Ages:
Between 30 months and 18 years
Trial Updated:
06/24/2024
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer, Oncology
Register for Updates
Registry of Older Patients With Cancer
NCT01137825
Recruiting
RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
06/24/2024
Locations: Seby B. Jones Cancer Center, Boone, North Carolina
Conditions: Chronic Myeloproliferative Disorders, Cognitive/Functional Effects, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
NCT05948475
Recruiting
This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Messino Cancer Centers, Asheville, North Carolina
Conditions: Cholangiocarcinoma
Register for Updates
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
NCT05658497
Recruiting
The primary objectives of the study are to estimate the risk of major congenital malformations (MCMs) in infants born to women with multiple sclerosis (MS) who were exposed to diroximel fumarate (DRF) at any time from 2 weeks after the first day of their last menstrual period (LMP) up through the first trimester of pregnancy and to comparatively evaluate pregnancy outcomes with MCMs in women with MS who were exposed to DRF at any time from 2 weeks after the first day of their LMP through the fir... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
06/21/2024
Locations: IQVIA US Office, Durham, North Carolina
Conditions: Multiple Sclerosis
Register for Updates